Peginterferon alfa-2b for mycosis fungoides [3]

Archives of Dermatology

Volumn 142, Issue 5, 2006, Pages 649-651

  Yanagi, Teruki ^a   Shimizu, Tadamichi ^b   Ujiie, Hideyuki ^b   Ito, Miki ^b   Abe, Riichiro ^b   Tsuji Abe, Yukiko ^b   Hige, Shuhei ^b   Shimizu, Hiroshi ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ETRETINATE; INTERLEUKIN 2 RECEPTOR; PEGINTERFERON ALPHA2B; PSORALEN; RIBAVIRIN; STEROID;

AGED; ANAMNESIS; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

AGED; ANTIVIRAL AGENTS; ARM; DIAGNOSIS, DIFFERENTIAL; DRUG CARRIERS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LEG; MALE; MYCOSIS FUNGOIDES; SKIN NEOPLASMS;

EID: 33646570244     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.5.649     Document Type: Letter

References (9)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965.
2. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991;24:247-252.
3. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanism. J Am Acad Dermatol. 2004;50:375-379.
4. Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sezary syndrome: regulation by interferon alfa and interleukin 12. J Am Acad Dermatol. 2001;44:28-32.
5. Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002;95:569-575.
6. Wollina U, Looks A, Meyer J, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol. 2001;44:253-260.
7. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468-473.
8. Miertusova S, Bonin S, Trevisan G, Stanta G. Mycosis fungoides is not associated with hepatitis C virus infection. Br J Dermatol. 2004;151:1108-1110.
9. Kasper B, Moehler T, Neben K, Ho AD, Goldschmidt H. Combination therapy of thalidomide and peginterferon in patients with progressive multiple myeloma. Ann Oncol. 2004;15:176-177.